2022 Autumn Conference
08 – 09 September, 2022 // Boston Park Plaza, Boston, MA
Distinguished Poster Award Recipient:
|
|||
| A general theory of construct enrichment: Inclusion criteria for symptom structure not severity (Hopkins; Abstract) | |||
|
View all Poster PDFs and Abstracts |
|||
8 September 2022 |
|||
| Welcome from the President | Gary Sachs slides video |
||
| Session 1: New challenges in Alzheimer’s and Dementia – Adapting to the new environment | Chairs: Rhoda Au Judith Jaeger |
||
| New approaches to cognitive endpoints in confirmatory trials of early Alzheimer’s Disease | Judith Jaeger slides video |
||
| How can we use digital technology to augment conventional cognitive assessments? | Kristin Hannesdottir* Gul Erdemli slides video |
||
| Scaling functional neurophysiology to clinical trials in Alzheimer’s and other neurodegenerative conditions | Brian Murphy slides video |
||
| Developing barrier-breaking approaches in Alzheimer’s trials – global cohort characterization, clinical trials, and healthcare delivery | Rhoda Au slides video |
||
| Commentary: Concepts of interest and outcome measurement tools at different stages of development | Lorenzo Guizzaro slides video |
||
| Panel discussion | Facilitator: Judith Jaeger video |
||
|
Session 2: Suicidality: What have we learned after a decade of research? What challenges remain? |
Chairs: Larry Alphs David Sheehan |
||
| Introduction and agenda for session | Larry Alphs slides video |
||
| Real world assessments of suicide ideation and behavior. Challenges and next steps. | Eric Chan slides video |
||
| Veteran suicide surveillance and development and evaluation of the REACH VET clinical program | John McCarthy slides video |
||
| Research in suicide ideation and behavior: Problems faced. What we have learned. Directions for the future. | Jill Harkavy-Friedman slides video |
||
| Insights into study design and methodology for assessing suicide ideation and behavior in clinical trials for safety and efficacy: Hurdles and advances | David Sheehan* |
||
| Statistical challenges and potential solutions for assessing suicide ideation and behavior endpoints | Kari Nations slides video |
||
| Panel discussion | Facilitator: Larry Alphs video |
||
|
Concurrent Working Group Sessions |
|||
| Algorithms/flags to identify clinical inconsistency in the use of rating scales in CNS RCTs | Chairs: Jonathan Rabinowitz Nina Schooler |
||
| Behavioral and psychiatric symptoms in dementia (BPSD) Apathy | Chairs: Krista Lanctôt David Miller slides |
||
| Digital biomarkers decision process | Chairs: Vikas Mohan Sharma Diane Hoffman slides |
||
| Joint ISCTM/ECNP COVID-19 methodologies blueprint | Chairs: Dragana Bugarski-Kirola Gerard Dawson Kemi Olugemo |
||
| Orphan diseases | Chairs: Joan Busner Gahan Pandina slides |
||
|
Poster Session |
Poster PDFs and Abstracts | ||
9 September 2022 |
|||
| Session 3: Hot Topic Breakfast Session: Methodological implications of world events that impede subject recruitment | Chairs: Atul Mahableshwarkar Michael Ropacki |
||
| Are critical world events confounding factors for clinical trials? | Steven Targum slides video |
||
| Recent impacts on CNS clinical trial recruitment: Qualitative assessment of the impacts and resultant methodological assessment | Michael Ropacki slides video |
||
| Impact of patient recruitment before and during COVID shelter-in-place: What do unblinded data reveal | Kerensa Saljooqi slides video video (discussion) |
||
| Impact of war in Ukraine on clinical trials: Lessons learned from a phase 3 program in schizophrenia | Debra Phillips* slides video (discussion only) |
||
| Commentary: Estimands, power and general considerations
Panel discussion |
Discussant: Lorenzo Guizzaro slides videoFacilitator: Michael Ropacki video |
||
| Session 4: Post-traumatic stress disorder as a prototype disorder for heterogeneity in neuropsychiatry | Chairs: Lori Davis Tom Neylan |
||
| Introduction | Lori Davis slides video |
||
| Translational biomarkers and novel compounds to address the unmet need in the civilian PTSD population | Kerry Ressler slides video |
||
| Drug development in heterogeneous disorders: When to target subgroups? Case example in PTSD | Thomas Neylan slides video |
||
| Rationale and aims of a Phase 2, multi-center, multi-arm, randomized, placebo-controlled, double-blind, adaptive platform study to evaluate the safety, tolerability, and efficacy of potential therapeutic interventions in active duty service members and veterans with posttraumatic stress disorder | Elyse Katz slides video |
||
| Operational complexities when managing PTSD trials | Kerrin Young slides video |
||
| Panel discussion | Facilitator: Lori Davis video |
||
| Session 5: Algorithms, clinical outcomes, and digital biomarkers – Next generation endpoints | Chairs: Adam Butler Jane Tiller |
||
| Introduction | Jane Tiller slides video |
||
| Verification, analytical validation, and clinical validation for biometric technologies | Ariel Dowling slides video |
||
| Voice My Health: A multi-modal approach to digital phenotyping | John Reynders slides video |
||
| Gaps in the evidentiary requirements framework: Traversing the last mile for regulatory qualification of sensor-derived digital endpoints | Ritu Kapur slides video |
||
| US regulatory considerations | Ian Marcus slides Anita Bajaj slides video |
||
| Panel discussion | Facilitator: Adam Butler video |
||
| Meeting adjourns | Gary Sachs slides video |
||
| *Slides and/or video not released | |||